A special key for unlocking the door to targeted therapies of breast cancer.
Personalized medicine and targeted therapy is the best hope for patients with cancer. C-Met-HGF/SF inhibition may be an effective cancer treatment for ductal carcinoma of the breast as it is expected to be an important signalling target in a large number of malignancies.
Department of Obstetrics and Gynaecology, Medical Faculty, University of Oslo, Division Akershus University Hospital, Norway. kristina.lindemann@ahus.no
Kristina
K
Lindemann
Nadia
N
Harbeck
Ernst
E
Lengyel
James H
JH
Resau
D001943:Breast Neoplasms / Q000628:therapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000628:therapy*; D017228:Hepatocyte Growth Factor / Q000627:therapeutic use*; D006801:Humans; D019859:Proto-Oncogene Proteins c-met / Q000187:drug effects* / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
D017228:Hepatocyte Growth Factor; D019859:Proto-Oncogene Proteins c-met; D018719:Erb-b2 Receptor Tyrosine Kinases